67 related articles for article (PubMed ID: 1535386)
1. [PI metabolism and Ca mobilization in patients with platelet dysfunction].
Fuse I; Hattori A; Higuchi W; Shibata A
Nihon Rinsho; 1992 Feb; 50(2):237-43. PubMed ID: 1535386
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of platelet shape change, inositol metabolism, and Ca mobilization in patients with platelet dysfunction].
Fuse I; Hattori A; Higuchi W
Rinsho Byori; 1992 Mar; 40(3):287-96. PubMed ID: 1518180
[TBL] [Abstract][Full Text] [Related]
3. Characterization of platelet cytoplasmic Ca2+ mobilization in patients with congenital cyclo-oxygenase deficiency and with defective platelet aggregation to A23187.
Fuse I; Hattori A; Nagayama R
Nihon Ketsueki Gakkai Zasshi; 1989 Dec; 52(8):1522-33. PubMed ID: 2516953
[TBL] [Abstract][Full Text] [Related]
4. Defective signal transduction through the thromboxane A2 receptor in a patient with a mild bleeding disorder: deficiency of the inositol 1,4,5-triphosphate formation despite normal G-protein activation.
Mitsui T; Yokoyama S; Shimizu Y; Katsuura M; Akiba K; Hayasaka K
Thromb Haemost; 1997 May; 77(5):991-5. PubMed ID: 9184416
[TBL] [Abstract][Full Text] [Related]
5. Hemorrhagic thrombocytopathy with platelet thromboxane A2 receptor abnormality: defective signal transduction with normal binding activity.
Ushikubi F; Okuma M; Kanaji K; Sugiyama T; Ogorochi T; Narumiya S; Uchino H
Thromb Haemost; 1987 Apr; 57(2):158-64. PubMed ID: 2955539
[TBL] [Abstract][Full Text] [Related]
6. Defective signal transduction induced by thromboxane A2 in a patient with a mild bleeding disorder: impaired phospholipase C activation despite normal phospholipase A2 activation.
Fuse I; Mito M; Hattori A; Higuchi W; Shibata A; Ushikubi F; Okuma M; Yahata K
Blood; 1993 Feb; 81(4):994-1000. PubMed ID: 8428006
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effect of GBH on platelet aggregation through inhibition of intracellular Ca2+ mobilization in activated human platelets.
Park WH; Kim HK; Nam KS; Shon YH; Jeon BH; Moon SK; Kim MG; Kim CH
Life Sci; 2004 Nov; 75(25):3063-76. PubMed ID: 15474558
[TBL] [Abstract][Full Text] [Related]
8. Pathogenetic analysis of five cases with a platelet disorder characterized by the absence of thromboxane A2 (TXA2)-induced platelet aggregation in spite of normal TXA2 binding activity.
Fuse I; Hattori A; Mito M; Higuchi W; Yahata K; Shibata A; Aizawa Y
Thromb Haemost; 1996 Dec; 76(6):1080-5. PubMed ID: 8972034
[TBL] [Abstract][Full Text] [Related]
9. Platelet lipoxygenase inhibitors attenuate thrombin- and thromboxane mimetic-induced intracellular calcium mobilization and platelet aggregation.
Nyby MD; Sasaki M; Ideguchi Y; Wynne HE; Hori MT; Berger ME; Golub MS; Brickman AS; Tuck ML
J Pharmacol Exp Ther; 1996 Aug; 278(2):503-9. PubMed ID: 8768697
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the defective signal transduction mechanism through the platelet thromboxane A2 receptor in a patient with polycythemia vera.
Ushikubi F; Ishibashi T; Narumiya S; Okuma M
Thromb Haemost; 1992 Jan; 67(1):144-6. PubMed ID: 1535462
[TBL] [Abstract][Full Text] [Related]
11. KRDS, a peptide derived from human lactotransferrin, inhibits thrombin-induced thromboxane synthesis by a cyclooxygenase-independent mechanism.
Lévy-Toledano S; Grelac F; Caen JP; Maclouf J
Thromb Haemost; 1995 May; 73(5):857-61. PubMed ID: 7482416
[TBL] [Abstract][Full Text] [Related]
12. 2-(2-Br-phenyl)-8-methoxy-benzoxazinone (HPW-RX2), a direct thrombin inhibitor with a suppressive effect on thromboxane formation in platelets.
Wu CC; Wang TW; Wang WY; Hsieh PW; Wu YC
Eur J Pharmacol; 2005 Dec; 527(1-3):37-43. PubMed ID: 16313903
[TBL] [Abstract][Full Text] [Related]
13. Dissociation of Ca2+ mobilization from breakdown of phosphatidylinositol 4,5-bisphosphate in activated human platelets.
Kito M; Narita H; Takamura H; Park HJ; Matsuura T; Tanaka K
J Biochem; 1986 Apr; 99(4):1277-80. PubMed ID: 3011769
[TBL] [Abstract][Full Text] [Related]
14. Genistein, a protein tyrosine kinase inhibitor, inhibits thromboxane A2-mediated human platelet responses.
Nakashima S; Koike T; Nozawa Y
Mol Pharmacol; 1991 Apr; 39(4):475-80. PubMed ID: 2017148
[TBL] [Abstract][Full Text] [Related]
15. Effects of etamsylate on platelet functions and arachidonic acid metabolism.
Okuma M; Takayama H; Sugiyama T; Sensaki S; Uchino H
Thromb Haemost; 1982 Dec; 48(3):330-3. PubMed ID: 6819650
[TBL] [Abstract][Full Text] [Related]
16. The protective effects of paclitaxel on platelet aggregation through the inhibition of thromboxane A2 synthase.
Lee JJ; Yu JY; Lee JH; Zhang WY; Kim TJ; Myung CS; Yun YP
Arch Pharm Res; 2010 Mar; 33(3):387-94. PubMed ID: 20361303
[TBL] [Abstract][Full Text] [Related]
17. Pathogenesis of a bleeding disorder characterized by platelet unresponsiveness to thromboxane A2.
Fuse I; Higuchi W; Aizawa Y
Semin Thromb Hemost; 2000; 26(1):43-5. PubMed ID: 10805281
[TBL] [Abstract][Full Text] [Related]
18. Acetyl glycerylphosphorylcholine aggregates human platelets through two distinct pathways, both dependent on arachidonic acid metabolism.
Macconi D; Morzenti G; Livio M; Morelli C; Cassina G; Remuzzi G
Lab Invest; 1985 Feb; 52(2):159-68. PubMed ID: 3155816
[TBL] [Abstract][Full Text] [Related]
19. Antiplatelet activity of carnosol is mediated by the inhibition of TXA2 receptor and cytosolic calcium mobilization.
Lee JJ; Jin YR; Lim Y; Hong JT; Kim TJ; Chung JH; Yun YP
Vascul Pharmacol; 2006 Sep; 45(3):148-53. PubMed ID: 16916624
[TBL] [Abstract][Full Text] [Related]
20. Impairment of phosphatidylinositol metabolism in a patient with a bleeding disorder associated with defects of initial platelet responses.
Lages B; Weiss HJ
Thromb Haemost; 1988 Apr; 59(2):175-9. PubMed ID: 2838922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
